Human cardiotoxic drugs delivered by soaking and microinjection induce cardiovascular toxicity in zebrafish

• Published in: Journal of applied toxicology 2014-02, Vol.34 (2), p.139-148
• Main Authors: Zhu, Jun-Jing, Xu, Yi-Qiao, He, Jian-Hui, Yu, Hang-Ping, Huang, Chang-Jiang, Gao, Ji-Min, Dong, Qiao-Xiang, Xuan, Yao-Xian, Li, Chun-Qi
• Format: Article
• Language: English
• Subjects: Abnormalities, Drug-Induced - pathology; animal model; Animals; arrhythmia; Aspirin - toxicity; Biocompatibility; cardiotoxicity; Cardiotoxins - toxicity; Cardiovascular system; cardiovascular toxicity; Clomipramine - toxicity; Cyclophosphamide - toxicity; Danio rerio; Disease Models, Animal; drug screen; Drugs; Edema - chemically induced; Edema - pathology; Freshwater; Gentamicins - toxicity; Heart Diseases - chemically induced; Heart Diseases - pathology; Heart Rate - drug effects; Heart Ventricles - drug effects; Heart Ventricles - physiopathology; Human; Hydrochlorides; Larva - drug effects; microinjection; Microinjections; Nimodipine - toxicity; Pericardium - drug effects; Pericardium - pathology; Pharmacology; Quinidine - toxicity; Sulfates; Terfenadine - toxicity; Tetracycline - toxicity; Tetracyclines; Toxicity; toxicity assessment; Toxicity Tests; Verapamil - toxicity; Yolk Sac - drug effects; Yolk Sac - pathology; Zebrafish
• ISSN: 0260-437X; 1099-1263
• DOI: 10.1002/jat.2843

ABSTRACT Cardiovascular toxicity is a major challenge for the pharmaceutical industry and predictive screening models to identify and eliminate pharmaceuticals with the potential to cause cardiovascular toxicity in humans are urgently needed. In this study, taking advantage of the transparency of larval zebrafish, Danio rerio, we assessed cardiovascular toxicity of seven known human cardiotoxic drugs (aspirin, clomipramine hydrochloride, cyclophosphamide, nimodipine, quinidine, terfenadine and verapamil hydrochloride) and two non‐cardiovascular toxicity drugs (gentamicin sulphate and tetracycline hydrochloride) in zebrafish using six specific phenotypic endpoints: heart rate, heart rhythm, pericardial edema, circulation, hemorrhage and thrombosis. All the tested drugs were delivered into zebrafish by direct soaking and yolk sac microinjection, respectively, and cardiovascular toxicity was quantitatively or qualitatively assessed at 4 and 24 h post drug treatment. The results showed that aspirin accelerated the zebrafish heart rate (tachycardia), whereas clomipramine hydrochloride, cyclophosphamide, nimodipine, quinidine, terfenadine and verapamil hydrochloride induced bradycardia. Quinidine and terfenadine also caused atrioventricular (AV) block. Nimodipine treatment resulted in atrial arrest with much slower but regular ventricular heart beating. All the tested human cardiotoxic drugs also induced pericardial edema and circulatory disturbance in zebrafish. There was no sign of cardiovascular toxicity in zebrafish treated with non‐cardiotoxic drugs gentamicin sulphate and tetracycline hydrochloride. The overall prediction success rate for cardiotoxic drugs and non‐cardiotoxic drugs in zebrafish were 100% (9/9) as compared with human results, suggesting that zebrafish is an excellent animal model for rapid in vivo cardiovascular toxicity screening. The procedures we developed in this report for assessing cardiovascular toxicity in zebrafish were suitable for drugs delivered by either soaking or microinjection. Copyright © 2013 John Wiley & Sons, Ltd. In this study we assessed cardiovascular toxicity of seven known human cardiotoxic drugs (aspirin, clomipramine hydrochloride, cyclophosphamide, nimodipine, quinidine, terfenadine and verapamil hydrochloride) and two non‐cardiovascular toxicity drugs (gentamicin sulphate and tetracycline hydrochloride) in zebrafish larvae using six specific phenotypic endpoints: heart rate, heart rhythm, pericardial edema, circ